Earnings Roundup: Biogen's Tecfidera Wins More Share

Biogen's (BIIB) dominance in multiple sclerosis drove sales 50% higher in the first quarter, as Tecfidera successfully expanded market share.

Apr 24, 2014 at 9:30AM

Biogen (NASDAQ:BIIB) remains a market leader in treating multiple sclerosis, an autoimmune disease that affects more than 1.1 million people in the U.S. and Europe.

The company has launched a host of widely successful MS therapies over the past decade, including blockbuster Avonex and Tysabri. However, competition in the form of oral drugs from Novartis (NYSE:NVS) and Sanofi (NYSE:SNY) have cut into Avonex's market share.

Given that Biogen has responded to that competitive threat with its own oral drug, Tecfidera, let's take a closer look at the company's first-quarter results.

BIIB Chart

BIIB data by YCharts

A big, global market
According to Express Scripts, spending on MS medication is going to grow roughly 12% a year through 2016. That's solid growth given that MS is unfortunately already the second most costly specialty drug category, costing insurers more than $46 per member per year in 2013.

The market share leader in MS treatment is Teva's (NYSE:TEVA) Copaxone, an injectible therapy that loses patent protection next month. Teva has been battling to keep generic biosimilars from Mylan and Momenta at bay.

The Supreme Court recently decided it would hear Teva's case, which may insulate it from the generic threat a bit longer. Assuming the FDA OKs it, Mylan could launch its biosimlar before the court reaches a decision; however, if the Court sides with Teva, Mylan would then be forced to pay damages.

Regardless, Copaxone's patent expiration may open a door for market share growth for competing therapies, including newly launched oral MS drugs from Novartis, Sanofi, and Biogen.

Novartis' Gilenya was the first oral MS therapy to win approval, and its first to market advantage led to sales of more than $1.9 billion in 2013.

Sanofi's Aubagio was the second oral MS drug to clear the FDA. Its sales have been growing quickly; however, the drug hasn't achieved Gilenya's success. Last year, Aubagio sales totaled $278 million.

While those two drugs had a head start at winning market share from prior generation drugs, both face a bigger challenge this year given that Biogen's Tecfidera, which won FDA approval in March 2013, has already become the most widely prescribed oral MS drug in the U.S., and is now launching in European markets.

Biogen sold more than $500 million worth of Tecfidera in the first quarter, $460 million of which was generated in the United States. That performance helped lift Biogen's overall sales by 51% to $2.1 billion in the first quarter.

While Tecfidera was the star of Biogen's quarter, Avonex also posted solid growth after sales were essentially unchanged from a year ago in the fourth quarter of 2013. In the first quarter, sales of Avonex grew from $746 million last year to $761 million.

Biogen's results also benefited from its decision to acquire all the rights to Tysabri from Elan for a little over $3 billion last year. As a result, Biogen now collects 100% of Tysabri's global sales, which totaled $441 million during the quarter.

Earnings miss ... but not to worry
Despite Tecfidera's multibillion dollar blockbuster run rate and a return to growth for Avonex, Biogen's profitability slipped in the first quarter as operating income declined from 36% of total revenue to 31.5%.

The slip in margin contributed to earnings per share that came in shy of Street forecasts. The company reported that EPS grew 25% year over year to $2.47 in the first quarter, but analysts were expecting the company to earn $2.56.

However, investors shouldn't overreact to the earnings miss because Biogen's guidance calls for sales growing 26% to 28% this year, producing EPS of between $11.35 and $11.45. Given that the Street is currently guess-timating for EPS of $11.32, I think analysts should soon be boosting their forecasts.

Similarly, investors should keep in mind that Biogen's balance sheet remains in great shape, with more than $1.26 billion in cash.

Fool-worthy final thoughts
That cash gives Biogen plenty of firepower to help win scripts for its newly approved hemophilia drug, Alprolix. Alprolix won the FDA green-light in March as a factor IX treatment to help control bleeding episodes in hemophilia B patients. Once launched, Alprolix will compete against Pfizer's $400 million a year Benefix.

Given the vast majority of Tecfidera's sales are in the U.S, the fact that Biogen won the drug's approval in the EU in February suggests sales will continue to build overseas as pricing agreements are reached. That should give investors plenty of reason to look beyond the first-quarter earnings miss. 

These 6 stock picks may grow even more quickly than Biogen
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd also owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers